U.S. Health Care Depth or Global Industry Reach? VHT vs. IXJ

VHT offers lower costs and broader U.S. healthcare exposure, with a 0.09% expense ratio, 411 holdings, and a 17.0% 1-year return versus IXJ’s 0.40% expense ratio, 114 holdings, and 12.4% return. IXJ provides global healthcare exposure but carries higher fees, slightly lower yield (1.46% vs. 1.72%), and marginally higher 5-year drawdown (-18.1% vs. -17.7%). The piece is comparative and portfolio-oriented rather than event-driven, so the market impact is limited.

Analysis

The key signal is not simply “U.S. vs global” exposure; it is that the cheaper, broader domestic vehicle is capturing the same mega-cap therapeutic winners while retaining more optionality in the second tier. That matters because healthcare leadership is still being driven by a narrow set of cash-generative franchises, so the more concentrated global wrapper is effectively paying up for currency and jurisdiction diversification without obvious compensation. In a market where investors are already crowding into defensives, fee drag becomes more visible because it compounds against low-beta, mid-single-digit expected returns.

Second-order, the global fund’s international mix adds a policy-and-FX overlay that can cut both ways. If the dollar weakens, IXJ’s translation effect improves, but that only offsets the structural hit from higher operating costs if non-U.S. pharma multiples re-rate at the same time. The U.S.-centric fund is cleaner exposure to the current winners in pricing power, GLP-1 growth, and capital-return capacity; that is why the domestic basket likely continues to outperform on a total-return basis unless there is a regime shift in FX or U.S. drug-pricing policy.

The contrarian point: the “defensive” label may be making investors underappreciate single-name concentration risk inside both products. If one or two weightings stumble on patent cliffs, trial disappointments, or reimbursement pressure, the sector ETF can underperform despite stable aggregate fundamentals. On that basis, the better trade is not a blind overweight to healthcare beta, but selective ownership of the dominant cash compounders and a willingness to fade the higher-fee global wrapper if equity markets remain stable and the dollar does not roll over sharply.

Key Decisions for Investors

• Long VHT / short IXJ for 3-6 months: express the view that lower fees plus broader U.S. breadth will continue to outperform unless USD weakens materially; target 3-5% relative spread with tight stop if DXY breaks down.
• Within healthcare exposure, prefer JNJ over ABBV for a 6-12 month hold: lower idiosyncratic patent-risk profile and stronger balance-sheet optionality make it the cleaner defensive compounder if sector multiples compress.
• Use ABBV only tactically on weakness: better as a cash-yield vehicle than a core beta holding; position size should be smaller given higher dependence on pipeline execution and sentiment around growth durability.
• If seeking sector defense, buy VHT on any 3-5% broad-market drawdown rather than chase IXJ: the entry improves expected forward return because the fee differential is large relative to the sector’s underlying volatility.
• Avoid hedging equity risk with IXJ as a proxy long: the currency overlay can dilute the hedge; use direct U.S. healthcare exposure or index hedges instead.